CordenPharma International, an expert contract manufacturing organization (CMO), has completed the acquisition of US-based carbohydrate synthesis firm Ancora Pharmaceuticals' technology.
The acquisition will offer CordenPharma with important capacity in the growing market of synthetic carbohydrates.
Harris & Harris Group (TINY) is an investor in transformative companies enabled by disruptive science.
Ancora Pharmaceuticals chairperson Misti Ushio said, "We are excited for Ancora to join CordenPharma, which will expand Ancora's chemistry expertise into an organization that can provide scale and cGMP manufacturing of complex synthetic carbohydrates."
CordenPharma's API business chief operating officer Christian Ewers said, "Together, Ancora and CordenPharma are equipped to provide a full range of carbohydrate synthesis and production needs, from early stage discovery research through to commercial cGMP manufacturing, at any scale."
Ancora offers the solution to the long-standing obstacle to carbohydrate-based therapeutic development, which has been economical access to pure and defined carbohydrate structures.
